# Trade Mark Journal No.2026/005 30 January 2026

## WO0000001896337 (5)

Office of origin: United States of America

Date of International Registration:12 November 2025
Date of designation in the UK: 12 November 2025

The mark consists of H HALOZYME in stylized font with a dot above the stylized H.

Class 5
  Drug delivery agents in the form of liquid for subcutaneous delivery that facilitate the delivery of pharmaceutical preparations; enzymes for medical purposes, namely, for facilitating delivery of fluids or pharmaceuticals; drug delivery agents consisting of pharmaceuticals containing enzymes that facilitate delivery of fluids and a wide range of pharmaceuticals; pharmaceutical preparations for use in the treatment and prevention of metabolic conditions and disorders, endocrine conditions and disorders, diabetes, diabetic complications, hormonal diseases and disorders, dermatological conditions and disorders, and for the treatment of cancer and in hydration; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in aesthetic skin treatments; hyaluronic acid for pharmaceutical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures; enzymes for medical purposes, namely, recombinant human hyaluronidase formulation for use in in-vitro fertilization procedures.

Halozyme, Inc.

Representative: Gene K. Park, Morgan, Lewis & Bockius LLP,, One Market, Spear Street Tower, San Francisco CA 94105, UNITED STATES OF AMERICA